Randomized, Split-Face/Décolleté Comparative Trial of Procedure Enhancement System for Fractional non-Ablative Laser Resurfacing Treatment

J Drugs Dermatol. 2017 Jul 1;16(7):707-710.


<p>INTRODUCTION: A topical proprietary procedural enhancement system (PES) containing a combination of active ingredients including a tripeptide and hexapeptide (TriHex Technology™, Alastin Procedure Enhancement Invasive System, ALASTIN Skincare™, Inc., Carlsbad, CA) has been used successfully to aid in healing and improve symptomatology following resurfacing procedures.</p> <p>METHODS: PES (Gentle Cleanser, Regenerating Skin Nectar with TriHex Technology™, Ultra Nourishing Moisturizer with TriHex Technology™, Soothe + Protect Recovery Balm, Broad Spectrum 30+ Sunscreen) was compared to a basic regimen (Aquaphor™, Cerave™ cleanser, Vanicream™, Alastin Broad Spectrum 30+ Sunscreen) in a split face/ décolleté trial following fractional non-ablative thulium-doped resurfacing treatment to the face or décolleté. The skin was pre-conditioned and treated during and after the procedure using the two regimens.</p> <p>RESULTS: A blinded investigator rated the PES statistically superior to the basic regimen on healing post-laser treatment on day 4 based on lentigines, texture, and Global Skin Quality. Subjects also reported 'better looking and feeling' skin on the PES side.</p> <p>CONCLUSION: PES appears to improve healing post-non ablative thulium-doped resurfacing treatment to the face/décolleté in comparison with standard of care.</p> <p><em>J Drugs Dermatol. 2017;16(7):707-710.</em></p>.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Dermatologic Surgical Procedures / methods
  • Face / pathology
  • Female
  • Humans
  • Lasers, Gas / therapeutic use*
  • Plasma Skin Regeneration / methods
  • Single-Blind Method
  • Skin Aging / drug effects*
  • Skin Aging / pathology*
  • Skin Cream / administration & dosage*
  • Sunscreening Agents / administration & dosage*
  • Thorax / drug effects
  • Thorax / pathology
  • Treatment Outcome


  • Sunscreening Agents